Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Austrian biotechnology company Intercell has signed an exclusive agreement with Swiss group Novartis for the marketing and distribution of Intercell's vaccine candidate to prevent Japanese encephalitis, in Japan and Korea.
Subscribe to our email newsletter
This expands the commercialization agreement between Intercell and Novartis to these territories, which previously were not covered by the initial marketing and distribution agreement for Intercell’s Japanese encephalitis vaccine signed in 2006.
Under the terms of this agreement, Novartis receives the exclusive marketing and distribution rights in Japan and Korea and obtains a distribution margin on all product sales in these territories. Additional financial details were not disclosed.
Gerd Zettlmeissl, CEO of Intercell, said: “Japanese encephalitis is endemic to Japan and Korea and poses a significant risk, particularly to children. It was a priority for Intercell to identify a very strong marketing partner for these markets, where the disease is a major public health threat and we are convinced that Novartis – with its global reach – is ideally suited.”